Investment strategy

An early-stage fund with deep sector expertise

Catalyzing an investment 
market to address spinal 
cord repair.

Recent advances in science and technology have made recovery from paralysis a real possibility.

We target near-term functional improvement, while also backing the ultimate goal of biological repair of the spinal cord. Our strategy is guided by the priorities of those living with a spinal cord injury. We focus on curative therapies for motor and sensory deficits and leave the important work of care and adaptation to others.

SCI Ventures is uniquely positioned
to de-risk assets for a 
broad range of adjacent 
neurological conditions.

We invest in technologies targeted at SCI. There are many similarities between SCI and other conditions including stroke, neurodegenerative diseases or neural circuit disorders such as epilepsy or pain. The technologies we back have the potential to yield high impact beyond the SCI community.

We use strict criteria to assess a company’s investment impact, focusing on prospective financial return.

We aim to make an impact, by identifying the most innovative technologies and supporting at an early stage the most entrepreneurial management teams, regardless of where they are in the world.  We assess each company for its scientific maturity and potential for clinical impact.

Clinical impact
Scientific maturity
Commercially attractive

Collaborative expertise and decision-making

Our Investment Committee makes portfolio decisions after drawing upon the expertise of our Scientific Advisory Committee. Both committees include representatives from the research foundations who support us and we foster frequent collaboration throughout the international SCI ecosystem.

We bring to the table not just funding, but access to a rich network that spans:

Discovery science
Standardized pre-clinical models
Patient advocacy
Scientific Advisory Board

Our mission is guided 
by scientific rigor

Our advisory council is made up of leading multidisciplinary experts in spinal cord injury R&D. At the frontline of academic research, they inform our strategy with the latest findings.

Murray Blackmore, PhD 

Professor Marquette University
Leader in nerve regeneration & genetic control

Rob Brownstone, MD, PhD

Professor of Neurosurgery, Brain Research UK
Head of the Division of Neurosurgery UCL

Edelle Field-Fote, PhD

Director, Spinal Cord Injury Research, Shepherd Center 
Professor, Emory University School of Medicine, Division of Physical Therapy  
Professor of the Practice, Georgia Institute of Technology, School of Biological Sciences 

Phil Horner, PhD

Professor of Neuroregeneration
Director, Center for Neuroregeneration at Houston Methodist

Chet Moritz, PhD

Professor of Electrical & Computer Engineering, University of Washington,
Co-Director, Center for Neurotechnology

Armin Curt, MD, PhD

Professor for Paraplegiology, University of Zurich,
Chief and Director Spinal Cord Injury Center

By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.